Market Risers: AstraZeneca, Compass Group, easyJet

Broker Ratings

The stock price for AstraZeneca with ticker code: LON:AZN has moved up 2.25% or 195 points during today’s session so far. Market buyers have remained optimistic throughout the session. The periods high figure was 8982 and hitting a low of 8825.94. The amount of shares exchanged has so far reached 1,224,569 with the daily average traded share volume around 2,273,368. A 52 week high for the stock is 8982 around 314 points different to the previous business close and a 52 week low sitting at 6736 which is a difference of 1932 points. AstraZeneca now has a 20 simple moving average of 8486.06 and now the 50 day SMA of 8471.68. The market capitalisation is now £137,609.38m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Friday, September 24, 2021 at 12:04:20 PM GMT with the stock price trading at 8863 GBX.

Shares of Compass Group ticker lookup code: LON:CPG has stepped up 1.5% or 22 points throughout today’s trading session so far. Investors seem confident during the session. Range high for the period so far is 1493.5 and hitting a low of 1455. The number of shares traded by this point in time totalled 298,478 with the average number of shares traded daily being 3,095,047. The 52 week high for the share price is 1657.03 some 188.53 points difference from the previous days close and putting the 52 week low at 1029 is a variance of 439.5 points. Compass Group now has a 20 SMA at 1492.3 and also a 50 day moving average of 1501.23. Market capitalisation for the company is £26,591.00m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Compass Group being recorded at Friday, September 24, 2021 at 11:52:31 AM GMT with the stock price trading at 1490.5 GBX.

Shares of easyJet EPIC code: LON:EZJ has increased 4.42% or 28.89 points in today’s trading session so far. Investors are a positive bunch throughout the session. Range high for the period has seen 683.41 meanwhile the session low reached 644.6. Volume total for shares traded at this point reached 1,641,146 with the average number of shares traded daily being 7,413,234. The stock 52 week high is 921.89 which is 268.09 points difference from the previous close and the 52 week low at 385.43 making a difference of 268.37 points. easyJet now has a 20 moving average of 662.48 and now the 50 day moving average now of 691.05. The current market cap is £5,172.24m at the time of this report. Share price is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for easyJet being recorded at Friday, September 24, 2021 at 11:52:27 AM GMT with the stock price trading at 682.69 GBX.

Share on:

Latest Company News

AstraZeneca secures US Approval for fixed-duration Calquence regimen in CLL

AstraZeneca’s Calquence plus venetoclax has been approved in the US as the first all-oral, 14-month treatment option for adults with CLL and SLL, following Phase III data showing improved progression-free survival versus chemoimmunotherapy.

AstraZeneca Q4 and FY 2025: Strong sales growth and pipeline momentum

Excerpt In FY 2025, AstraZeneca achieved 9% reported revenue growth and a 45% increase in reported EPS, reflecting strong commercial execution and pipeline progress.

AstraZeneca Plc begins trading on the New York Stock Exchange

AstraZeneca has started trading its ordinary shares on the NYSE for the first time, aligning its listings across New York, London and Stockholm under a harmonised structure.

AstraZeneca signs $1.2bn obesity drug collaboration with CSPC

Under a new agreement with CSPC Pharmaceuticals, AstraZeneca will advance eight programmes targeting obesity and weight-related conditions, initially progressing four assets through Phase I.

AstraZeneca to move Nasdaq listing to NYSE

AstraZeneca PLC has notified of the voluntary withdrawal of its American Depositary Shares and certain debt securities from The Nasdaq Stock Market LLC.

AstraZeneca’s Enhertu plus pertuzumab approved in US for 1st-line HER2-positive breast cancer

AstraZeneca and Daiichi Sankyo have received US FDA approval for Enhertu in combination with pertuzumab as a 1st-line treatment for adults with unresectable or metastatic HER2-positive breast cancer.

    Search

    Search